

ICMJE DISCLOSURE FORM

Date: February 7, 2023

Your Name: Xavier Adhoute

Manuscript Title: COSMIC-312, a disappointing result. Is that so surprising?

Manuscript number (if known): ATM-23-421

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	none	
3	Royalties or licenses	___ None	
4	Consulting fees	Bayer	To x adhoute

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Bayer	To the Institution
		Servier	To x adhoue
		Ipsen	To x adhoue
		EISAI	To x adhoue
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	Ipsen	
		Milan	
		Gilead	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

Board member [lectures, presentations, speaker's bureaus, manuscript writing], Consultancy: Bayer, Ipsen, Eisai, Servier.
 Support for attending meetings and/or travel: Ipsen, Milan, Gilead

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: February 7, 2023

Your Name: Marc Bourlière

Manuscript Title: COSMIC-312, a disappointing result. Is that so surprising?

Manuscript number (if known): ATM-23-421

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	Merck-Schering Plow	To M Bourlière
		Gilead	To M Bourlière
		Janssen	To M Bourlière
		Roche Abbvie	To M Bourlière

		BMS	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Vertex	
		Boehringer-Ingelheim	
		GSK	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	Gilead	
		Roche	
		Abbvie BMS	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

Board member [lectures, presentations, speaker's bureaus, manuscript writing or educational events], Consultancy: (Merck-Schering Plow, Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, GSK)

Support for attending meetings and/or travel: Gilead, Roche, Abbvie, BMS

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: February 7, 2023

Your Name: Rodolphe Anty

Manuscript Title: COSMIC-312, a disappointing result. Is that so surprising?

Manuscript number (if known): ATM-23-421

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	Bayer	To r Anty
		Ipsen	To r Anty
		Eisai	To r Anty

		Abbvie MSD Intercept	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead	To r Anty
		Bayer	
		Abbvie	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	Gilead Abbvie	To r Anty
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

Board member [Payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events], Consultancy: Gilead, Bayer, Eisai, Intercept, Abbvie, MSD, Ipsen
 Support for attending meetings and/or travel: Gilead, Abbvie

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.